Table 2. Association between AKR1B10 expression level, clinical parameters and disease-free survival/overall survival.

Clinical character	Category	No. of patients	Disease-free survival (months)			Overall survival (months)
			Mean	95% CI	p value	Mean	95% CI	p value
AKR1B10 expression	Low	45	47.04	36.45–57.63	0.006	51.18	41.51–60.84	0.007
	High	99	29.29	23.04–35.56		34.80	28.68–40.93
Age (years)	<55	97	35.73	28.78–42.69	0.644	40.62	34.02–47.22	0.716
	≥55	47	33.38	23.93–42.83		38.45	29.47–47.44
Gender	Male	122	31.73	25.90–37.57	0.015	36.56	30.94–42.18	0.009
	Female	22	53.59	38.44–68.73		58.73	45.57–71.91
Family history	No	125	33.94	27.97–39.91	0.357	38.74	33.03–44.44	0.290
	Yes	19	40.46	25.23–55.68		47.81	33.35–62.26
HBsAg	Negative	26	32.77	20.25–45.28	0.905	40.87	29.31–52.44	0.857
	Positive	118	35.39	29.13–41.65		39.77	33.79–45.75
alpha-fetoprotein (ng/ml)	<100	54	34.83	25.85–43.82	0.824	41.29	32.49–50.09	0.696
	≥100	90	34.60	27.61–41.60		39.15	32.46–45.84
Median size (cm)	<5	48	51.74	43.27–60.21	<0.001	60.91	52.50–69.32	<0.001
	≥5	96	24.52	18.71–30.32		29.50	23.75–35.25
Cirrhosis	No	15	22.33	10.09–34.57	0.198	31.53	18.46–44.61	0.347
	Yes	129	36.22	30.23–42.21		40.86	35.15–46.58
Tumor number	Single	90	40.98	33.57–48.40	0.008	45.74	38.87–52.62	0.004
	Multiple	54	25.14	17.51–32.77		30.33	22.57–38.10
TNM stage	I–II	51	46.74	38.77–54.72	<0.001	57.59	48.92–66.27	<0.001
	III–IV	93	25.22	19.24–31.20		30.29	24.41–36.17
Portal vein tumor thrombus	No	110	39.64	32.96–46.31	0.001	44.98	38.76–51.20	<0.001
	Yes	34	20.50	12.17–28.83		23.59	15.57–31.61
Lymph node metastasis	No	133	35.08	29.21–40.95	0.916	39.92	34.32–45.52	0.961
	Yes	11	33.09	15.08–51.11		39.64	23.60–55.67
Recurrence	No	96				32.52	26.29–38.75	<0.001
	Yes	48				54.82	46.22–63.43